Cancer Investigation · 2005 · 42 citations · 15 references
MedicineOncologyPharmacologyChemotherapyMedical OncologyPalliative OncologyChemotherapy Toxicity ManagementCombination ChemotherapyMetastatic Cancer ManagementPalliative ChemotherapyPancreatic CancerToxicity ManagementCancer-related SymptomsGemcitabine-based TherapyLocal Tumor ProgressionMetastatic Pancreatic CancerOxaliplatin-based TherapyPhase Ii InvestigationSecond-line ChemotherapyStable Disease Assessment
A phase II study was designed to evaluate the efficacy and safety of oxaliplatin as second-line treatment in patients with locally advanced or metastatic pancreatic cancer. Eighteen patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy, received oxaliplatin 130 mg/m2 i.v. every 21 days. Patients were treated until tumor progression or unacceptable toxicity. No objective response was observed among the 18 treated patients. Three (16.7%) patients had stable disease for > 2 months. A clinical benefit response was observed in five (27.7%) patients. Toxicity was mild. Oxaliplatin as second-line treatment for patients with unresectable pancreatic cancer is well tolerated and associated with improvement of tumor-related symptoms despite its failure to induce objective responses. LOHP merits further investigation in combination with other drugs as palliative treatment of pretreated patients with advanced pancreatic cancer.
15
Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.9K citations
Medicine, Oncology, Pharmacotherapy +16
One-Sample Multiple Testing Procedure for Phase II Clinical Trials
Thomas R. Fleming · Biometrics · 1982 · 997 citations
The role of DNA mismatch repair in platinum drug resistance.
Daniel Fink, S Nebel, Stefan Aebi et al. · PubMed · 1996 · 603 citations
Chemotherapy prolongs survival in inoperable pancreatic carcinoma
K Palmér, Michael Kerr, Gillian Knowles et al. · British journal of surgery · 1994 · 275 citations